Acceleron Pharma Inc. (XLRN)

43.19
NASDAQ : Health Technology
Prev Close 42.49
Day Low/High 42.76 / 44.35
52 Wk Low/High 37.01 / 56.91
Avg Volume 289.70K
Exchange NASDAQ
Shares Outstanding 53.08M
Market Cap 2.26B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
FDA Approves REBLOZYL® (luspatercept-aamt) For The Treatment Of Anemia In Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA Approves REBLOZYL® (luspatercept-aamt) For The Treatment Of Anemia In Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.

Acceleron Announces Luspatercept Presentations At The 61st American Society Of Hematology Annual Meeting

Acceleron Announces Luspatercept Presentations At The 61st American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that data from six clinical abstracts on luspatercept will...

Acceleron Reports Third Quarter 2019 Operating And Financial Results

Acceleron Reports Third Quarter 2019 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the...

Acceleron To Webcast Third Quarter 2019 Operating And Financial Results On November 6, 2019

Acceleron To Webcast Third Quarter 2019 Operating And Financial Results On November 6, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.

Acceleron Announces Topline Results From The Phase 2 Trial Of ACE-083 In Patients With Facioscapulohumeral Muscular Dystrophy

Acceleron Announces Topline Results From The Phase 2 Trial Of ACE-083 In Patients With Facioscapulohumeral Muscular Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with...

Acceleron Receives FDA Orphan Drug Designation For Sotatercept In Pulmonary Arterial Hypertension

Acceleron Receives FDA Orphan Drug Designation For Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA)...

Acceleron Reports Second Quarter 2019 Operating And Financial Results

Acceleron Reports Second Quarter 2019 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the...

Acceleron To Webcast Second Quarter 2019 Operating And Financial Results On August 5, 2019

Acceleron To Webcast Second Quarter 2019 Operating And Financial Results On August 5, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.

Acceleron Completes Target Enrollment In The PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Completes Target Enrollment In The PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with...

Acceleron Announces Retirement Of Director And Co-Founder Tom Maniatis

Acceleron Announces Retirement Of Director And Co-Founder Tom Maniatis

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from...

Celgene Corporation And Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation And Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.

Acceleron To Present At The UBS Global Healthcare Conference

Acceleron To Present At The UBS Global Healthcare Conference

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS...

Acceleron Reports First Quarter 2019 Operating And Financial Results

Acceleron Reports First Quarter 2019 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the...

Acceleron To Webcast First Quarter 2019 Operating And Financial Results On May 9, 2019

Acceleron To Webcast First Quarter 2019 Operating And Financial Results On May 9, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To The European Medicines Agency (EMA) For MDS And Beta-Thalassemia

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To The European Medicines Agency (EMA) For MDS And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients...

Acceleron Announces Departure Of Chief Medical Officer

Acceleron Announces Departure Of Chief Medical Officer

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K.

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low...

Acceleron Discontinues Development Of Phase 1 Molecule ACE-2494

Acceleron Discontinues Development Of Phase 1 Molecule ACE-2494

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic...

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA)...

Acceleron Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Acceleron Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the...

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Here's how to trade XLRN stock right now.

Acceleron To Webcast Fourth Quarter And Full Year 2018 Operating And Financial Results On February 27, 2019

Acceleron To Webcast Fourth Quarter And Full Year 2018 Operating And Financial Results On February 27, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.

Acceleron To Present At Two Upcoming Healthcare Investor Conferences

Acceleron To Present At Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming...

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Announces Pricing Of Public Offering Of Common Stock

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it...

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Announces Proposed Public Offering Of Common Stock

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to...

Acceleron Announces Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood

Acceleron Announces Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of...

Acceleron To Webcast Presentation At The 37th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At The 37th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an...

Acceleron Announces Luspatercept Phase 3 MEDALIST And BELIEVE Presentations Selected For "Best Of ASH" By The American Society Of Hematology

Acceleron Announces Luspatercept Phase 3 MEDALIST And BELIEVE Presentations Selected For "Best Of ASH" By The American Society Of Hematology

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively,...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...

Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted...

TheStreet Quant Rating: D+ (Sell)